SVRASavara Inc.
Price
+40%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 10% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for SVRA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim inhalation solution ("MOLBREEVI" or "molgramostim"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”).
In the company’s own words · 10-K filed Mar 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jun 8, 2026Amendment of 2024 Omnibus Incentive Plan On June 4, 2026, the stockholders of Savara Inc. (“Savara”) approved an amendment to the Savara Inc. 2024 Omnibus Incentive Plan (the “2024 Plan”), to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000 shares (the “2024 Plan …Director or officer change · Form 8-K
- Mar 13, 2026On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,795 square feet of office space located at 19 W. College Avenue, Suite 200, Yardley, PA 19067.Material agreement entered · Form 8-K
- Jan 27, 2026On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated March 26, 2025 (the “Loan Agreement”), with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent.Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.